Trial Profile
Safety and Efficacy of Ribavirin –free regimen of Ombitasvir/Paritaprevir/Ritonavir for dialysis patients infected with Hepatitis C Virus.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 14 Nov 2017
Price :
$35
*
At a glance
- Drugs Dasabuvir (Primary) ; Ombitasvir/paritaprevir/ritonavir (Primary)
- Indications Hepatitis C
- Focus Adverse reactions; Therapeutic Use
- 14 Nov 2017 New trial record
- 24 Oct 2017 Results presented at The Liver Meeting 2017: 68th Annual Meeting of the American Association for the Study of Liver Diseases